Intuitive Surgical Earnings Plunge 11% as Growth Hits 4-Year Low
Will the sudden slowdown in robotic surgery adoption permanently derail Intuitive Surgical's premium valuation?
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple?
Johnson & Johnson Earnings +9.9% Surge With Dividend Hike
Can Johnson & Johnson’s latest earnings surge and dividend hike still justify its premium valuation for long-term investors?